A Multinational, Prospective, Open Labelled, Non-controlled, Non-interventional Post-authorisation Study of Turoctocog Alfa Pegol (N8-GP) During Long-term Routine Prophylaxis and Treatment of Bleeding Episodes in Patients With Haemophilia A
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Turoctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Acronyms pathfinder9
- Sponsors Novo Nordisk
- 03 Dec 2020 Status changed from not yet recruiting to recruiting.
- 05 Oct 2020 New trial record